Squamous cell lung carcinoma (sqNSCLC) accounts for 25% to 30% of all non-small cell lung cancer (NSCLC) cases and is associated with a worse prognosis.
Although immune checkpoint inhibitors improve outcomes in advanced sqNSCLC, the true benefit of chemotherapy plus anti-PD-(L)1 in patients with advanced PD-L1-negative sqNSCLC is unclear.
